Enovis (NYSE:ENOV) Raised to “Buy” at Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Monday.

Several other research firms also recently commented on ENOV. BTIG Research raised their price objective on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Needham & Company LLC boosted their price objective on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, UBS Group reiterated a “buy” rating and issued a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Enovis currently has an average rating of “Buy” and a consensus target price of $47.43.

Enovis Trading Up 0.2%

Shares of ENOV stock opened at $21.86 on Monday. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -1.06 and a beta of 1.46. Enovis has a 1 year low of $21.00 and a 1 year high of $38.56. The firm has a fifty day moving average price of $23.03 and a 200-day moving average price of $27.18.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to analysts’ expectations of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.Enovis’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts predict that Enovis will post 2.79 earnings per share for the current year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert acquired 1,000 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the purchase, the insider directly owned 43,640 shares in the company, valued at approximately $1,112,820. The trade was a 2.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 5,000 shares of company stock valued at $121,983 in the last quarter. 2.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Enovis by 2.0% in the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after purchasing an additional 125,460 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Enovis by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after purchasing an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new position in Enovis during the third quarter valued at $83,435,000. Hood River Capital Management LLC grew its stake in shares of Enovis by 20.3% in the 2nd quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company’s stock worth $54,426,000 after buying an additional 292,950 shares in the last quarter. Finally, River Road Asset Management LLC increased its holdings in shares of Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after buying an additional 46,289 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.